Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCL

Video

Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.

Robert M. Dean, MD, assistant professor, Department of Medicine, School of Medicine, member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center, physician, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma (MCL).

CAR T-cell therapy could be utilized as consolidative treatment for patients with MCL who achieve less than a complete response with frontline chemoimmunotherapy, says Dean. Historically, consolidative treatment has consisted of high-dose chemotherapy and autologous stem cell transplant after induction therapy for younger, fitter patients with MCL.

Whether patients who achieve a deep molecular remission with undetectable minimal residual disease (MRD) require consolidative treatment remains an area of active clinical investigation, Dean explains. However, there may be rationale to suggest that CAR T-cell therapy could be a consolidative treatment for patients without the need for autologous transplant, Dean explains. Moreover, MRD testing could inform which patients could benefit from this approach rather than giving CAR T-cell therapy after clinical relapse or failure of BTK inhibitor therapy, concludes Dean.

Recent Videos
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.